×
About 38,863 results

ALLMedicine™ Acute Myeloid Leukemia Center

Research & Reviews  12,148 results

miR-196b-TLR7/8 signaling axis regulates innate immune signaling and myeloid maturation...
https://doi.org/10.1158/1078-0432.CCR-22-1598
Clinical Cancer Research : an Official Journal of the Ame... Gamlen HA, Romer-Seibert JS et. al.

Aug 10th, 2022 - DNMT3A mutations confer a poor prognosis in acute myeloid leukemia (AML), but the molecular mechanisms downstream of DNMT3A mutations in disease pathogenesis are not completely understood, limiting targeted therapeutic options. The role of microRN...

Sorafenib maintenance after hematopoietic stem cell transplantation improves outcome of...
https://doi.org/10.1007/s12185-022-03427-4
International Journal of Hematology; Aydin S, Passera R et. al.

Aug 10th, 2022 - In a retrospective analysis, 21 acute myeloid leukemia patients receiving single-agent sorafenib maintenance therapy in complete remission (CR) after hematopoietic stem cell transplantation (HSCT) were compared with a control group of 22 patients ...

c-Myc plays a critical role in the antileukemic activity of the Mcl-1-selective inhibit...
https://doi.org/10.1007/s10495-022-01756-7
Apoptosis : an International Journal on Programmed Cell D... Liu S, Qiao X et. al.

Aug 10th, 2022 - Acute myeloid leukemia (AML) is an aggressive disease with a low 5-year overall survival rate of 29.5%. Thus, more effective therapies are in need to prolong survival of AML patients. Mcl-1 is overexpressed in AML and is associated with poor progn...

Analysis of the Influence of Serum MMP-2 and vWF Levels on the Predictive Value of Risk...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9325568
Contrast Media & Molecular Imaging; Liu M, Yang Q et. al.

Aug 9th, 2022 - The expression of serum MMP-2 and von Willebrand factor (vWF) in patients with acute myeloid leukemia (AML) at different risks and their predictive value and prognostic impact were investigated. A total of 105 AML patients admitted to our hospital...

Analysis of Risk Factors of Coagulation Dysfunction and Hemorrhage in Newly Diagnosed H...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9300275
Contrast Media & Molecular Imaging; Xu A, Liu P et. al.

Aug 9th, 2022 - To explore whether and why abnormal coagulation function and hemorrhage can appear in patients with hyperleukocytic acute myeloid leukemia (HAML). We retrospectively reviewed the charts of 724 acute myeloid leukemia (AML) patients admitted with a ...

see more →

Guidelines  12 results

NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021.
https://doi.org/10.6004/jnccn.2021.0002
Journal of the National Comprehensive Cancer Network : JN... Pollyea DA, Bixby D et. al.

Jan 7th, 2021 - The NCCN Guidelines for Acute Myeloid Leukemia (AML) provide recommendations for the diagnosis and treatment of adults with AML based on clinical trials that have led to significant improvements in treatment, or have yielded new information regard...

Hematopoietic Cell Transplantation in the Treatment of Newly Diagnosed Adult Acute Myel...
https://doi.org/10.1016/j.bbmt.2020.09.020
Biology of Blood and Marrow Transplantation : Journal of ... Dholaria B, Savani BN et. al.

Sep 24th, 2020 - The role of hematopoietic cell transplantation (HCT) in the management of newly diagnosed adult acute myeloid leukemia (AML) is reviewed and critically evaluated in this evidence-based review. An AML expert panel, consisting of both transplant and...

Clinical Practice Guideline for Systemic Antifungal Prophylaxis in Pediatric Patients W...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7499615
Journal of Clinical Oncology : Official Journal of the Am... Lehrnbecher T, Fisher BT et. al.

May 28th, 2020 - To develop a clinical practice guideline for systemic antifungal prophylaxis in pediatric patients with cancer and hematopoietic stem-cell transplantation (HSCT) recipients. Recommendations were developed by an international multidisciplinary pane...

NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018.
https://doi.org/10.6004/jnccn.2017.0157
Journal of the National Comprehensive Cancer Network : JN... Mesa RA, Jamieson C et. al.

Oct 7th, 2017 - Myeloproliferative neoplasms (MPNs) are a group of heterogeneous disorders of the hematopoietic system that include myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET). PV and ET are characterized by significant thromboh...

Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology.
https://doi.org/10.6004/jnccn.2017.0116
Journal of the National Comprehensive Cancer Network : JN... O'Donnell MR, Tallman MS et. al.

Jul 9th, 2017 - Acute myeloid leukemia (AML) is the most common form of acute leukemia among adults and accounts for the largest number of annual deaths due to leukemias in the United States. This portion of the NCCN Guidelines for AML focuses on management and p...

see more →

Drugs  30 results see all →

Clinicaltrials.gov  1,694 results

Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia
https://clinicaltrials.gov/ct2/show/NCT02688140

Aug 5th, 2022 - Acute promyelocytic leukemia (APL) is a rare subtype of acute myeloid leukemia (AML) characterized by consistent clinical, morphologic, and genetic features. According to the FAB classification APL is designated as"M3 leukemia" and assigned to the...

BMS-986253 in Myelodysplastic Syndromes
https://clinicaltrials.gov/ct2/show/NCT05148234

Aug 5th, 2022 - Background: The myelodysplastic syndromes (MDS) are a group of clonal bone marrow neoplasms characterized by ineffective hematopoiesis, cytopenia, and high risk for transformation to acute myeloid leukemia (AML). MDS is primarily a disease of the ...

IFN-γ to Treat Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) That Has Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation
https://clinicaltrials.gov/ct2/show/NCT04628338

Aug 5th, 2022 - Allogeneic hematopoietic stem cell transplantation (alloSCT) can cure patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). However, relapsed AML/MDS is the most significant single cause of treatment failure, and the major...

A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leuk...
https://clinicaltrials.gov/ct2/show/NCT04161885

Aug 5th, 2022 - The main objective of this study is to evaluate the efficacy of venetoclax in combination with azacitidine to improve Relapse Free Survival (RFS) in Acute Myeloid Leukemia (AML) participants compared to Best Supportive Care (BSC) when given as mai...

Clinical Trial of Oral Ciprofloxacin and Etoposide in Subjects With Resistant Acute Myeloid Leukemia (AML)(UF-AML-CE-101)
https://clinicaltrials.gov/ct2/show/NCT02773732

Aug 5th, 2022 - This study will look at: any side effects that occur, the effectiveness of the study drug, and how your disease reacts to ciprofloxacin in combination with etoposide. This study will try to find the highest tolerated dose of ciprofloxacin without ...

see more →

News  1,655 results

Treating Older AML Patients and Managing Unique Toxicities
https://www.medscape.com/viewarticle/964537

Jul 20th, 2022 - This transcript has been edited for clarity. Gail J. Roboz, MD: My name is Dr Gail Roboz. I'm a professor of medicine and director of the leukemia program at Weill Cornell Medicine and the NewYork-Presbyterian Hospital in New York City. It is my t...

Low Albumin Associated With Early Mortality in AML
https://www.medscape.com/viewarticle/976987

Jul 12th, 2022 - The study covered in this summary was published on researchsquare.com as a preprint and has not yet been peer reviewed. Key Takeaway Low serum albumin is significantly associated with 60-day mortality in primary acute myeloid leukemia (AML). Why T...

No Survival Gain From High-Dose Cytarabine Consolidation in AML
https://www.medscape.com/viewarticle/976065

Jun 23rd, 2022 - The study was published on researchsquare.com as a preprint and has not yet been peer reviewed. Key Takeaway Regarding consolidation therapy for younger patients with acute myeloid leukemia (AML), there was no survival benefit from taking high-dos...

Adverse-Risk Acute Myeloid Leukemia
https://www.medscape.com/viewarticle/964535

Jun 16th, 2022 - This transcript has been edited for clarity. Gail J. Roboz, MD: Hi, everyone. My name is Dr Gail Roboz, I'm a professor of medicine. I run the leukemia program at Weill Cornell Medicine at the NewYork-Presbyterian Hospital in New York City. It is ...

Quizartinib Doubles Overall Survival in FLT3-ITD-Positive AML
https://www.medscape.com/viewarticle/975457

Jun 13th, 2022 - The potent oral FLT3 inhibitor quizartinib more than doubled overall survival among patients newly diagnosed with FLT3-ITD-positive acute myeloid leukemia (AML) compared with standard chemotherapy, new phase 3 data show. Among adults who received ...

see more →

Patient Education  6 results see all →